NZ750131B2 - Microorganism having acyltransferase activity and uses thereof - Google Patents
Microorganism having acyltransferase activity and uses thereof Download PDFInfo
- Publication number
- NZ750131B2 NZ750131B2 NZ750131A NZ75013117A NZ750131B2 NZ 750131 B2 NZ750131 B2 NZ 750131B2 NZ 750131 A NZ750131 A NZ 750131A NZ 75013117 A NZ75013117 A NZ 75013117A NZ 750131 B2 NZ750131 B2 NZ 750131B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- methionine
- microorganism
- polypeptide
- acetyl
- acyltransferase
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 85
- 230000000694 effects Effects 0.000 title claims abstract description 60
- 108091022082 Acyl transferases Proteins 0.000 title abstract description 95
- 102000019632 Acyl transferases Human genes 0.000 title abstract description 95
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims abstract description 93
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 84
- 229920001184 polypeptide Polymers 0.000 claims abstract description 64
- 229960004452 Methionine Drugs 0.000 claims abstract description 41
- 229920000023 polynucleotide Polymers 0.000 claims abstract description 38
- 239000002157 polynucleotide Substances 0.000 claims abstract description 38
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000000397 acetylating Effects 0.000 claims abstract description 7
- 150000001413 amino acids Chemical group 0.000 claims description 50
- 101700061430 SAT19 Proteins 0.000 claims description 11
- 101700081234 TTR Proteins 0.000 claims description 11
- 241000235013 Yarrowia Species 0.000 claims description 7
- 241000186249 Corynebacterium sp. Species 0.000 claims description 4
- 241000488157 Escherichia sp. Species 0.000 claims description 4
- 241000235088 Saccharomyces sp. Species 0.000 claims description 4
- 241000490645 Yarrowia sp. Species 0.000 claims description 3
- 230000002708 enhancing Effects 0.000 abstract description 6
- 229940099459 N-acetylmethionine Drugs 0.000 description 42
- 239000002609 media Substances 0.000 description 37
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 25
- 239000007788 liquid Substances 0.000 description 23
- 210000004027 cells Anatomy 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 19
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 16
- 229960000318 kanamycin Drugs 0.000 description 16
- 230000001131 transforming Effects 0.000 description 16
- 229940100228 Acetyl Coenzyme A Drugs 0.000 description 14
- ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 241000589776 Pseudomonas putida Species 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 108091007521 restriction endonucleases Proteins 0.000 description 11
- 240000008371 Bacillus subtilis Species 0.000 description 8
- 235000014469 Bacillus subtilis Nutrition 0.000 description 8
- 229940075615 Bacillus subtilis Drugs 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 230000000875 corresponding Effects 0.000 description 8
- 238000004925 denaturation Methods 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000012138 yeast extract Substances 0.000 description 8
- 229940041514 Candida albicans extract Drugs 0.000 description 7
- 241000186226 Corynebacterium glutamicum Species 0.000 description 7
- 241000147019 Enterobacter sp. Species 0.000 description 7
- 241000201640 Yarrowia lipolytica PO1f Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 210000000170 Cell Membrane Anatomy 0.000 description 6
- 241000186216 Corynebacterium Species 0.000 description 6
- 241000639457 Pseudovibrio sp. Species 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 241000588722 Escherichia Species 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 5
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 210000000349 Chromosomes Anatomy 0.000 description 4
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 4
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- 210000004767 Rumen Anatomy 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241000235015 Yarrowia lipolytica Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 235000013379 molasses Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108010023063 Bacto-peptone Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 229960002079 calcium pantothenate Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 2
- 230000036849 Clc Effects 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229920002024 GDNA Polymers 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 108010078762 Protein Precursors Proteins 0.000 description 2
- 102000014961 Protein Precursors Human genes 0.000 description 2
- 241001408112 Pseudovibrio Species 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000007644 bacto marine broth Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000005824 corn Nutrition 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- 239000007222 ypd medium Substances 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DVARTQFDIMZBAA-UHFFFAOYSA-O Ammonium nitrate Chemical compound [NH4+].[O-][N+]([O-])=O DVARTQFDIMZBAA-UHFFFAOYSA-O 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229960000633 Dextran Sulfate Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione Transferase family Human genes 0.000 description 1
- 108010070675 Glutathione Transferase family Proteins 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L Iron(II) chloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L Iron(II) sulfate Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BZHCGFBZBPVRFE-UHFFFAOYSA-N Monopotassium phosphite Chemical compound [K+].OP(O)[O-] BZHCGFBZBPVRFE-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-UHFFFAOYSA-N N-Acetyl-L-methionine Chemical compound CSCCC(C(O)=O)NC(C)=O XUYPXLNMDZIRQH-UHFFFAOYSA-N 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000005819 Potassium phosphonate Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N Silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 150000002741 methionine derivatives Chemical class 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01001—Amino-acid N-acetyltransferase (2.3.1.1)
Abstract
The present invention relates to a novel polypeptide of acyltransferase or a microorganism comprising the same; a composition for preparing N-acetyl-L-methionine comprising the polypeptide or microorganism; and a method for preparing N-acetyl-L-methionine using the polypeptide or microorganism. In addition, the present invention relates to a polynucleotide encoding the polypeptide and an expression vector comprising the polynucleotide. Since the microorganism comprising the novel acyltransferase of the present invention enhances the activity of the acyltransferase, the microorganism of the present invention can be efficiently used to produce N-acetyl-L-methionine by acetylating L-methionine. ddition, the present invention relates to a polynucleotide encoding the polypeptide and an expression vector comprising the polynucleotide. Since the microorganism comprising the novel acyltransferase of the present invention enhances the activity of the acyltransferase, the microorganism of the present invention can be efficiently used to produce N-acetyl-L-methionine by acetylating L-methionine.
Description
DESCRIPTION
MICROORGANISM HAVING ACYLTRANSFERASE
ACTIVITY AND USES THEREOF
Technical Field
The present disclosure relates to a polypeptide having an acyltransferase
activity or a microorganism including the same; a composition for preparing N-
acetyl-L-methionine, the composition including the polypeptide or microorganism;
and a method of preparing N-acetyl-L-methionine using the polypeptide or
microorganism. Further, the present disclosure relates to a polynucleotide
encoding the polypeptide and an expression vector including the polynucleotide.
Background Art
N-Acetylmethionine, which is a derivative of methionine, has similar
efficacy to methionine, but it can reduce methionine-specific flavors and can be
added in a large amount compared to methionine when added to foods. In the
case of animals having a rumen, when methionine is used as a feed additive, it is
first used by rumen microorganisms and thus is not absorbed by the animals,
whereas N-acetylmethionine is a rumen-protected amino acid that is absorbed after
passing through the rumen and reaching the intestine. The degradation resistance
of N-acetyl-DL-methionine at the rumen is known (Amos et al., Journal of Animal
Science, 1974, 39(3), pp. 612-617). Accordingly, the production of N-
acetylmethionine has industrial value, and particularly, it is preferable to provide an
L-type amino acid having a high absorption rate and high bioavailability when used
as a feed additive, and therefore research and development of N-acetyl-L-
methionine is required. In the case of enzymes reported to convert methionine to
N-acetylmethionine, YncA of Escherichia coli is unique (US 8,143,031 B2). In
this document, it was found that acetyl-CoA was used indirectly through a DTNB
analysis method to measure the inactivity of YncA, and it was not found that N-
acetylmethionine was produced. Further, it has not been found that N-
acetylmethionine is actually produced by the transformant transformed by YncA.
Disclosure
Technical Problem
The present inventors have conducted continuous efforts to produce N-
acetyl-L-methionine through a microbial fermentation or an enzymatic reaction,
and thus have searched for microorganisms capable of producing N-acetyl-L-
methionine and discovered six new acyltransferases. Further, they have found
that N-acetyl-L-methionine can be produced economically at a high concentration
using the novel acyltransferase of the present disclosure or a microorganism
expressing the novel acyltransferase, as compared with a known acyltransferase.
Based on this finding, the present disclosure has been completed.
Technical Solution
An object of the present disclosure is to provide a microorganism having
an acyltransferase activity, the microorganism including a polypeptide represented
by an amino acid sequence of any one of SEQ ID NOS. 1 to 6 or an amino acid
sequence having 90% or more homology to the amino acid sequence.
Another object of the present disclosure is to provide a polypeptide having
an acetyltransferase activity, the polypeptide being represented by an amino acid
sequence of any one of SEQ ID NOS. 1 to 6 or an amino acid sequence having
90% or more homology to the amino acid sequence.
Still another object of the present disclosure is to provide a polynucleotide
encoding the polypeptide.
Still another object of the present disclosure is to provide an expression
vector including the polynucleotide.
Still another object of the present disclosure is to provide a composition
for preparing N-acetyl-L-methionine from L-methionine, the composition
including, as an active ingredient: (i) the microorganism or a culture thereof; (ii)
the polypeptide; or a combination thereof.
Still another object of the present disclosure is to provide a method of
preparing N-acetyl-L-methionine, including: acetylating L-methionine using (i) the
microorganism or a culture thereof; (ii) the polypeptide; or a combination thereof.
Advantageous Effects
Since the microorganism including a novel acyltransferase according to
the present disclosure has enhanced acyltransferase activity, this microorganism
can be efficiently used for producing N-acetyl-L-methionine by acetylating L-
methionine.
Best Mode for Invention
In order to accomplish the above objects, an aspect of the present
disclosure provides a microorganism having acyltransferase activity, the
microorganism including a polypeptide represented by an amino acid sequence of
any one of SEQ ID NOS. 1 to 6 or an amino acid sequence having 90% or more
homology thereto.
The term “acyltransferase” used in the present disclosure refers to an
enzyme having an activity of transferring an acyl group from a donor to a receptor.
In the present disclosure, the donor is not limited as long as it can provide an acyl
group to a receptor, but may specifically be acetyl coenzyme A (acetyl-CoA).
Further, as used herein, the receptor is not limited as long as it can receive an acyl
group from a donor, but may specifically be L-methionine.
Specifically, the acyltransferase may be derived from genus Pseudomonas,
genus Bacillus, genus Enterobacter, genus Pseudovibrio, genus Yarrowia, or genus
Corynebacterium. More specifically, the acyltransferase may be derived from
Pseudomonas putida, Bacillus subtilis, Enterobacter sp. 638, Pseudovibrio sp. FO-
BEG1, Yarrowia lipolytica, or Corynebacterium glutamicum.
Specifically, the acyltransferase may be a polypeptide having an amino
acid sequence of any one of SEQ ID NOS. 1 to 6. Further, the acyltransferase
may be a polypeptide having an amino acid sequence having 70% or more, 80% or
more, or 90% or more homology to an amino acid sequence of any one of SEQ ID
NOS. 1 to 6 and having an acyltransferase activity substantially the same as or
corresponding to that of the amino acid sequence of any one of SEQ ID NOS. 1 to
6. Further, the amino acid sequence having such homology and having an
acyltransferase activity substantially the same as or corresponding to that of the
amino acid sequence of any one of SEQ ID NOS. 1 to 6 may be an amino acid
sequence, a part of which is deleted, transformed, substituted, or added. It is
obvious that this case may also be included in the scope of the present disclosure.
The term “homology” used in the present disclosure refers to the degree of
identity of base or amino acid residues between sequences after aligning both
amino acid sequences or base sequences of a gene encoding a polypeptide in a
specific comparison region to be matched with each other as much as possible.
When the homology is sufficiently high, expression products of the corresponding
gene may have the same or similar activity. The percentage of the sequence
identity can be determined using a known sequence comparison program, for
example, BLAST (NCBI), CLC Main Workbench (CLC bio), MegAlign
(DNASTAR Inc), or the like.
The term “microorganism having an acyltransferase activity” used in the
present disclosure refers to a microorganism producing an acyltransferase in vivo or
in vitro. Specifically, since the microorganism of the present disclosure includes
a polypeptide having an amino acid sequence of any one of SEQ ID NOS. 1 to 6
and thus has an acyltransferase activity, it can transfer an acyl group to a receptor.
More specifically, the microorganism of the present disclosure has
acetyltransferase activity to L-methionine and thus can produce N-acetyl-L-
methionine. In the present disclosure, N-acetyl-L-methionine and N-
acetylmethionine are used interchangeably.
Additionally, the microorganism of the present disclosure includes not
only microorganisms which inherently contain a polypeptide having an amino acid
sequence of any one of SEQ ID NOS. 1 to 6, but also microorganisms in which the
activity of the polypeptide is enhanced as compared with an intrinsic activity.
That is, the production capacity of the acyltransferase can be imparted or enhanced
by natural or anthropogenic mutagenesis or species modification. The term
“enhancement” of polypeptide activity, as used herein, refers to improving the
active state of the polypeptide included in the microorganism. Enhancement of
polypeptide activity is not limited as long as it can enhance the activity of each
polypeptide, such as the enhancement of the activity of the target polypeptide, as
compared with a natural state or to a non-variation state of the polypeptide. For
example, the enhancement of polypeptide activity may be performed by a method
selected from i) increasing the number of copies of a polynucleotide encoding each
polypeptide, ii) modifying an expression sequence to increase the expression of the
polynucleotide, iii) modifying the polynucleotide sequence on the chromosome to
enhance the activity of each polypeptide, and iv) a combination thereof.
Specifically, the enhancement of polypeptide activity may be performed by a
method selected from a method of inserting a polynucleotide including a nucleotide
sequence encoding each polypeptide into a chromosome, a method of introducing
the polynucleotide into a microorganism through a vector system, a method of
introducing a promoter exhibiting an improved activity upstream of a base
sequence encoding each polypeptide or introducing each of the mutated
polypeptides into a promoter, a method of modifying the nucleotide sequence in the
′-UTR region, and a method of introducing a mutant of the base sequence
encoding each polypeptide, but the present disclosure is not limited thereto.
Further, in the present disclosure, the microorganism having an
acyltransferase activity may be used regardless of the origin of the microorganism
as long as it has an acyltransferase activity. For example, the microorganism may
be Escherichia sp., Corynebacterium sp., Saccharomyces sp., or Yarrowia sp.
More specifically, the microorganism may be Escherichia coli, Corynebacterium
glutamicum, Saccharomyces cerevisiae, or Yarrowia lipolytica, but is not limited
thereto.
Further, in the present disclosure, the microorganism having an
acyltransferase activity may be a microorganism having enhanced cell membrane
permeability of a donor and/or a receptor. As the method of increasing the cell
membrane permeability, a known method may be used. Specifically, processes of
freezing and thawing the microorganism may be repeated, but the present
disclosure is not limited thereto.
Further, in the present disclosure, the microorganism having an
acyltransferase activity may biosynthesize a receptor to which an acyl group is
transferred from a donor, but the present disclosure is not limited thereto.
Specifically, the microorganism of the present disclosure may produce N-acetyl-L-
methionine even when it is cultured in a medium to which L-methionine is not
added because it has an ability of producing L-methionine that is an acceptor of an
acyl group.
Further, in the present disclosure, the microorganism having an
acyltransferase activity may be a mutant microorganism into which a known
mutation is introduced with respect to a related mechanism such as a biosynthesis-
related pathway or a substrate releasing capacity-related mechanism in order to
enhance N-acetyl-L-methionine production ability separately from the
acyltransferase.
An aspect of the present disclosure provides a polypeptide having an
acetyltransferase activity, the polypeptide being represented by an amino acid
sequence of any one of SEQ ID NOS. 1 to 6 or an amino acid sequence having
90% or more homology to the amino acid sequence. Specifically, the
acetyltransferase activity may be an acetyltransferase activity to L-methionine.
The polypeptide is as described above.
Another aspect of the present disclosure provides a polynucleotide
encoding the polypeptide having an acetyltransferase activity, the polypeptide
being represented by an amino acid sequence of any one of SEQ ID NOS. 1 to 6 or
an amino acid sequence having 90% or more homology to the amino acid
sequence. The polypeptide is as described above.
For example, the polynucleotide may be a base sequence of any one of
SEQ ID NOS. 7 to 12, but is not limited thereto. Further, the polynucleotide may
include a base sequence encoding the same amino acid sequence due to genetic
code degeneracy, and a mutant thereof. For example, the polynucleotide may be
modified to have an optimal codon depending on the microorganism used.
Specifically, the polynucleotide may be a base sequence encoding an
amino acid sequence having 70% or more, 80% or more, or 90% or more
homology to the above base sequence and having an acyltransferase activity
substantially the same as or corresponding to that of the above base sequence.
Further, the polynucleotide may be a probe that can be prepared from a known
gene sequence, for example, it may be a sequence encoding a polypeptide having
an acyltransferase activity by hybridization with a complementary sequence to all
or part of the base sequence under stringent conditions. Here, the “stringent
conditions” refer to conditions where a specific hybrid is formed and a non-specific
hybrid is not formed. For example, the stringent conditions may include a
condition where genes having high homology, for example, genes having 80% or
more, specifically 90% or more, more specifically 95% or more, further
specifically 97% or more, or particularly specifically 99% or more homology are
hybridized and genes having lower homology are not hybridized, and a condition
where cleaning is performed one time, specifically two or three times under a salt
concentration and temperature corresponding to 60 C, 1×SSC, 0.1% SDS,
specifically 60 C, 0.1×SSC, 0.1% SDS, and more specifically 68 C, 0.1×SSC,
0.1% SDS, which are cleaning conditions for conventional hybridization,
(Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001)).
The probe used in the hybridization may be a part of a complementary
sequence of the base sequence. This probe may be prepared by PCR using a gene
fragment including such a base sequence as a template by using an oligonucleotide
prepared based on a known sequence as a primer. For example, as the probe, a
gene fragment having a length of about 300 bp may be used. More specifically,
when a gene fragment having a length of about 300 bp is used as the probe, as
cleaning conditions for hybridization, 50 C, 2×SSC, and 0.1% SDS are
exemplified.
Genes, polypeptide sequences encoded by the genes, and promoter
sequences, which are used in the present disclosure, may be obtained from known
databases, for example, GenBank of NCBI. However, the present disclosure is
not limited thereto.
Still another aspect of the present disclosure provides an expression vector
including the polynucleotide.
The expression vector including the polynucleotide according to the
present disclosure is an expression vector capable of expressing a target protein in a
suitable host cell, and refers to a polynucleotide product including an essential
control element operably linked so as to express a polynucleotide insert. Target
proteins may be obtained by transforming or transfecting the prepared
recombination vector in the host cell.
The expression vector including the polynucleotide according to the
present disclosure is not particularly limited, but includes Escherichia coli-derived
plasmids (pYG601BR322, pBR325, pUC118, and pUC119), Bacillus subtilis-
derived plasmids (pUB110 and pTP5), yeast-derived plasmids (YEp13, YEp24,
and YCp50), and Ti-plasmids that can be used for agrobacterium-mediated
transformation. Specific examples of phage DNA include -phages (Charon4A,
Charon21A, EMBL3, EMBL4, lambda gt10, lambda gt11, and lambda ZAP).
Further, virus vectors derived from animal viruses such as retrovirus, adenovirus,
and vaccinia virus, insect viruses such as baculovirus, double-stranded plant virus
(for example, CaMV), single-stranded virus, or Geminiviruses may also be used.
Moreover, as the vector of the present disclosure, a fusion plasmid (for
example, pJG4-5) to which nucleic acid expression activating protein (for example,
B42) is linked may be used. Further, in order to facilitate the purification of a
target protein recovered in the present disclosure, the plasmid vector may further
include other sequences as necessary. Such a fusion plasmid may include GST,
GFP, His-tag, or Myc-tag as a tag, but the fusion plasmid of the present disclosure
is not limited to the above examples.
Further, in the production of the fusion protein, a chromatography process
may be used, and in particular, the fusion protein may be purified by affinity
chromatography. For example, when glutathione-S-transferase is fused,
glutathione, which is a substrate of this enzyme, may be used. When
hexahistidine is used, a desired target protein can be easily recovered using a Ni-
NTA His-conjugated resin column (Novagen, USA).
In order to insert the polynucleotide of the present disclosure as a vector, a
method of cleaving purified DNA with a suitable restriction enzyme and inserting
the cleaved DNA into a restriction site or a cloning site of an appropriate vector
DNA may be used.
The polynucleotide encoding the polypeptide of the present disclosure
may be operably linked to a vector. The vector of the present disclosure may
additionally include a cis-element such as an enhancer, a splicing signal, a poly A
addition signal, a selection marker, and a ribosome binding sequence (SD
sequence), in addition to the promoter and nucleic acid of the present disclosure.
Examples of the selection marker may include chloramphenicol resistance,
ampicillin resistance, dihydrofolate reductase, and neomycin resistance, but
additional components operably linked by the above examples are not limited.
The term “transformation” as used herein refers to a phenomenon of introducing
DNA into the host cell to allow the DNA to serve as a factor of a chromosome or to
be replicated by chromosome integration completion and introducing external
DNA into a cell to cause an artificial genetic change.
An expression vector including a polynucleotide encoding the polypeptide
of the present disclosure or a part of the expression vector may be introduced into a
host cell. Here, a part of the expression vector refers to a portion of the
expression vector, the portion including a portion of the polynucleotide encoding
the polypeptide of the present disclosure so as to impart the acyltransferase activity
into the host cell. For example, T-DNA of Ti-plasmid transferred into the host
cell in agrobacterium-mediated transformation may be exemplified, but the present
disclosure is not limited thereto.
Any transformation method may be used for the transformation method of
the present disclosure, and may be easily carried out according to a method known
in the art. Generally, the transformation method may include a CaCl
precipitation method, a Hanahan method in which dimethyl sulfoxide (DMSO) is
used as a reduction material in the CaCl precipitation method to increase
efficiency, an electroporation method, a CaPO precipitation method, a protoplasm
fusion method, a stirring method using silicon carbide fiber, an agrobacterium-
mediated transformation method, a transformation method using PEG, a dextran
sulfate-mediated transformation method, a lipofectamine-mediated transformation
method, and a drying/inhibition-mediated transformation method. The method of
transforming a vector including a polynucleotide encoding the polypeptide of the
present disclosure is not limited to the above examples, and transformation or
transfection methods commonly used in the art may be used without limitation.
The kind of host cells used in the preparation of a transformant in the
present disclosure is not particularly limited as long as the polynucleotide of the
present disclosure is expressed. Specific examples of the host cells used in the
present disclosure may include bacteria of genus Escherichia such as E. coli;
bacteria of genus Bacillus such as Bacillus subtilis; bacteria of genus Pseudomonas
such as Pseudomonas putida; yeasts such as Saccharomyces cerevisiae and
Schizosaccharomyces pombe; animal cells; plant cells; and insect cells. Specific
examples of Escherichia coli strains that can be used in the present disclosure may
include CL41(DE3), BL21, and HB101, and specific examples of Bacillus subtilis
strains that can be used in the present disclosure may include WB700 and LKS87.
The transformant into which an expression vector including the
polynucleotide of the present disclosure is introduced may be in the form of a
transformed cell or an organism.
As the promoter in the present disclosure, any promoter may be used as
long as it is capable of expressing the polynucleotide of the present disclosure in
the host cell. For example, Escherichia coli or phage-derived promoters such as
trp promoter, lac promoter, PL promoter, and PR promoter; Escherichia coli-
infected or phage-derived promoters such as T7 promoter; CaMV35S, MAS or
histone promoter; and cj7 promoter (Korean Patent Application Publication No. 10-
2004-0107215) may be used. Further, artificially modified promoters such as tac
promoter may also be used.
Still another aspect of the present disclosure provides a method of
preparing N-acetyl-L-methionine, including: acetylating L-methionine using (i) the
microorganism of the present disclosure or a culture thereof; (ii) the polypeptide of
the present disclosure; or a combination thereof.
Specifically, the method includes: preparing N-acetyl-L-methionine,
including: acetylating L-methionine using (i) the microorganism of the present
disclosure or a culture thereof; (ii) the polypeptide of the present disclosure; or a
combination thereof; and recovering N-acetyl-L-methionine, which is the
acetylated L-methionine.
In the present disclosure, the “culturing” refers to growing the
microorganism under suitably controlled environmental conditions.
The culturing process of the present disclosure may be performed
according to a suitable medium and culture conditions, which are known in the art.
Such a culturing process may be easily adjusted by those skilled in the art
depending on the strain to be selected. In the above method, the process of
culturing the microorganism is not particularly limited, but may be conducted by a
batch culture method, a continuous culture method, or a fed-batch culture method,
which is known in the art. The medium used for culturing the microorganism of
the present disclosure and other culture conditions may be used without any
particular limitation as long as it can be used for culturing general microorganisms.
Specifically, the microorganism of the present disclosure may be cultured in a
general medium including a carbon source, a nitrogen source, a phosphorus source,
an inorganic compound, amino acid, and/or vitamin while controlling temperature,
pH, and the like under aerobic conditions.
In the present disclosure, examples of the carbon sources may include, but
are not limited to, carbohydrates such as glucose, fructose, sucrose, maltose,
mannitol, and sorbitol; alcohols such as saccharide alcohol, glycerol, pyruvic acid,
lactic acid, and citric acid; organic acids; and amino acids such as glutamic acid,
methionine, and lysine. Further, natural nutrient sources such as starch
hydrolysate, molasses, blackstrap molasses, rice bran, cassava, sugar cane residues,
and corn immersion liquids may be used. Specifically, carbohydrates such as
glucose and sterilized pretreated molasses (that is, molasses converted to reducing
sugars) may be used, and suitable amounts of other carbon sources may be
variously used without limitation. These carbon sources may be used alone or in
a combination of two or more.
Examples of the nitrogen sources may include inorganic nitrogen sources
such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate,
ammonium phosphate, ammonium carbonate, and ammonium nitrate; and organic
nitrogen sources, such as amino acids such as glutamic acid, methionine and
glutamine, peptone, NZ-amine, meat extracts, yeast extracts, malt extracts, corn
immersion liquids, casein hydrolysates, fish or degradation products thereof, and
defatted soybean cake or degradation products thereof. These nitrogen sources
may be used alone or in a combination of two or more. However, the present
disclosure is not limited thereto.
Examples of the phosphorus sources may include potassium phosphate,
potassium phosphite, and sodium-containing salts thereof. Examples of the
inorganic compound may include sodium chloride, calcium chloride, iron chloride,
magnesium sulfate, iron sulfate, manganese sulfate, and calcium carbonate, and
may further include, but are not limited thereto, amino acids, vitamins, and/or
suitable precursors. These media or precursors may be added to a culture in a
batch or continuous manner, but are not limited thereto.
In the present disclosure, the pH of a culture may be adjusted by adding a
compound such as ammonium hydroxide, potassium hydroxide, ammonia,
phosphoric acid, or sulfuric acid to a culture in an appropriate manner during the
culturing of microorganisms. Further, during the culturing of microorganisms, the
formation of bubbles may be suppressed by using a defoaming agent such as
aliphatic polyglycol ester. Further, oxygen or oxygen-containing gas may be
injected into a culture in order to maintain the aerobic state of the culture, or
nitrogen, hydrogen, or carbon dioxide gas may be injected into the culture in order
to maintain the anaerobic and non-aerobic states of the culture without injecting the
gas.
The temperature of the culture varies depending on the microorganism of
the present disclosure. Specifically, the temperature thereof may be 20 C to 50 C,
more specifically, 25 C to 40 C, but is not limited thereto. The culturing period
may be continued until the amount of a desired useful material is obtained.
Specifically, the culturing period may be 10 hours to 100 hours, but is not limited
thereto.
Further, the term “culture” as used herein refers to a product obtained after
culturing the microorganism of the present disclosure. The culture includes both a
form containing microorganisms and a form in which microorganisms are removed
by centrifugation or the like in a culture solution containing the microorganisms.
Further, in the present disclosure, L-methionine may be produced by the
microorganism of the present disclosure or may be added to the medium.
Further, in the step of recovering N-acetyl-L-methionine in the present
disclosure, targeted N-acetyl-L-methionine may be recovered from the culture
solution using a suitable method known in the related art according to the method
of culturing the microorganism of the present disclosure, for example, a batch
culture method, a continuous culture method, or a fed-batch culture method. For
example, centrifugation, filtration, anion exchange chromatography, crystallization,
HPLC, and the like may be used, and a combination of suitable methods known in
the art may be used.
The recovering step may include a separating step and/or a purifying step.
Still another aspect of the present disclosure provides a composition for
preparing N-acetyl-L-methionine from L-methionine, the composition including, as
an active ingredient: (i) the microorganism of the present disclosure or a culture
thereof; (ii) the polypeptide of the present disclosure; or a combination thereof.
The microorganism, culture, polypeptide, and N-acetyl-L-methionine are as
described above.
Mode for Invention
Hereinafter, the present disclosure will be described in more detail with
reference to Examples. However, these Examples are only illustrative of the
present disclosure, and the scope of the present disclosure is not limited to these
Examples.
Example 1: Selection of novel enzyme for producing N-
acetylmethionine
Example 1-1: Selection of microorganism for producing N-acetyl-L-
methionine
As microorganisms having an ability of producing N-acetyl-L-methionine,
N-acetylmethionine spots, which are products, were confirmed from six kinds of
randomly selected microorganism culture solutions (Pseudomonas putida, Bacillus
subtilis, Enterobacter sp. 638, Pseudovibrio sp. FO-BEG1, Yarrowia lipolytica
PO1f (ATCC MYA-2613 ), and Corynebacterium glutamicum ATCC 13032).
Specifically, Pseudomonas putida, Bacillus subtilis, Enterobacter sp. 638,
or Yarrowia lipolytica PO1f was inoculated in a 14 mL disposable culture tube
containing 3 mL of a liquid YPD medium (1% yeast extract, 2% bacto-peptone, 2%
glucose), and was shake-cultured for 24 hours under conditions of 30 C and
200 rpm to obtain a seed culture solution. 1 mL of the seed culture solution was
inoculated in a 250 mL corner-baffle flask filled with 24 mL of the liquid YPD
medium containing 0.5% (5 g/L) of methionine, and was shake-cultured for 24
hours under conditions of 30 C and 200 rpm.
Further, Pseudovibrio sp. FO-BEG1 was inoculated in a 14 mL disposable
culture tube containing 3 mL of a liquid BACTO Marine broth (Difco 2216)
medium, and was shake-cultured for 24 hours under conditions of 28C and
200 rpm to obtain a seed culture solution. 1 mL of the seed culture solution was
inoculated in a 250 mL corner-baffle flask filled with 24 mL of the liquid BACTO
Marine broth (Difco 2216) medium containing 0.5% (5 g/L) of methionine, and
was shake-cultured for 24 hours under conditions of 28C and 200 rpm.
Further, Corynebacterium glutamicum ATCC 13032 was inoculated in a
14 mL disposable culture tube containing 3 mL of a dedicated composite liquid
medium (ingredients shown below), and was shake-cultured for 24 hours under
conditions of 30 C and 200 rpm to obtain a seed culture solution. 1 mL of the
seed culture solution was inoculated in a 250 mL corner-baffle flask filled with
24 mL of the dedicated composite liquid medium containing 0.5% (5 g/L) of
methionine, and was shake-cultured for 24 hours under conditions of 37 C and
200 rpm.
<Composite liquid medium>
g glucose, 10 g peptone, 5 g yeast extract, 1.5 g urea, 4 g KH PO ,
8 g K HPO , 0.5 g MgSO 7H O, 100 µg biotin, 1000 µg thiamine HCl, 2000 µg
2 4 4 2
calcium pantothenate, 2000 µg nicotinamide, and 25 mg kanamycin (based on 1 L
distilled water)
After completion of the culturing, the culture solution was left in an oven
at 50 C overnight to be concentrated, and 1 µL of the concentrated culture solution
was analyzed using thin layer chromatography. 10 mM of a N-acetyl-L-
methionine reagent (Sigma Aldrich 01310) was used as a control group. The
same spot as the control group was confirmed from the culture liquid concentrate
of the above six kinds of microorganisms.
From the above results, it was predicted that each of the six kinds of
microorganisms having an ability of producing N-acetyl-L-methionine contains an
acyltransferase including L-methionine as a substrate.
Example 1-2: Confirmation of novel acyltransferase sequence
Methionine acyltransferase was selected from the six kinds of
microorganisms selected in Example 1-1.
Heterogeneous homology searches for the selected proteins were
performed by restricting the database to species of the microorganism based on an
amino acid sequence with YncA known as a conventional methionine
acyltransferase. As a result, all of the six kinds of searched enzymes were found
to have low homology with the YncA amino acid sequence, and the homology of
the Enterobacter sp. 638-derived acyltransferase sequence, which had the highest
homology, was 82%. Homologies of the respective yeasts with YncA are given in
Table 1.
From the above results, it is inferred that the above kinds of polypeptides
are polypeptides having novel acyltransferase activity lower than the homology of
a conventional acyltransferase, and the microorganisms including these
polypeptides are also microorganisms having novel acyltransferase activity which
has not been previously known.
[Table 1]
Homology (%) with YncA amino acid
sequence
Pseudomonas putida-derived 65
acyltransferase
Bacillus subtilis-derived acyltransferase 28
Enterobacter sp. 638-derived 82
acyltransferase
Pseudovibrio sp. FO-BEG1-derived 46
acyltransferase
Yarrowia lipolytica PO1f-derived 29
acyltransferase
Corynebacterium glutamicum-derived 28
acyltransferase
Example 2: Production of N-acetylmethionine through in vitro enzyme
conversion using novel acyltransferase
Example 2-1: Preparation of novel acyltransferase-introduced
Escherichia coli
Pseudomonas-derived, Bacillus-derived, Enterobacter-derived, and
Pseudovibrio-derived novel acyltransferase genes (SEQ ID NOS. 7, 8, 9, and 10)
were synthesized as codons optimized for Escherichia coli based on amino acid
sequences (SEQ ID NOS. 1, 2, 3 and 4) of the respective enzymes.
In order to obtain a Yarrowia-derived novel acyltransferase gene, gDNA
of Yarrowia lipolytica PO1f (ATCC MYA-2613 ) was extracted. A gene (SEQ
ID NO. 11) of a desired size and an amino acid sequence (SEQ ID NO. 5) of a
desired size were obtained by performing a polymerase chain reaction using
primers 1 and 2 with the gDNA as a template.
In order to obtain a Corynebacterium-derived novel acyltransferase gene,
Corynebacterium glutamicum ATCC 13032 was smeared on a solid medium with
streaks and then cultured overnight to obtain colonies. A gene (SEQ ID NO. 12)
having a size of about 0.5 kb and an amino acid sequence (SEQ ID NO. 6) having a
size of about 0.5 kb were obtained by performing PCR (polymerase chain reaction)
using primers 3 and 4 with the one colony as a template. In this case, the PCR
was performed by conducting denaturation at 94 C for 5 minutes, repeating
denaturation at 94 C for 30 seconds, annealing at 56 C for 30 seconds and
polymerization at 72 C for 1 minute 30 times, and then conducting a
polymerization reaction at 72 C for 7 minutes.
The six kinds of DNAs were treated with restriction enzymes NdeI and
XbaI and then ligated to a pUCtk vector treated with the same restriction enzymes.
The prepared recombinant plasmid was transformed by applying thermal shock to
Escherichia coli DH5α at 42 C for 90 seconds, and then those was smeared in an
LB solid medium containing kanamycin and cultured overnight at 37 C. One
colony obtained in the culture was inoculated in 3 mL of an LB liquid medium
containing kanamycin and cultured overnight, and then the recombinant plasmid
was recovered using a plasmid miniprep kit (Bioneer, Korea). Sequence
information of the recovered recombinant plasmid was confirmed by sequencing
(Macrogen, Korea), and the plasmids were named pUCtk-ppmat, pUCtk-bsmat,
pUCtk-entmat, pUCtk-pvmat, pUCtk-ylmat, and pUCtk-cgmat.
The colonies surviving after introducing the recombinant plasmid into
Escherichia coli BL21 (DE3) using thermal shock and smearing this in an LB solid
medium containing kanamycin were selected as transformants. The selected
transformants were named BL21(DE3)/pUCtk-ppmat (or E. coli CC03-9001),
BL21(DE3)/pUCtk-bsmat (or E. coli CC03-9002), BL21(DE3)/pUCtk-entmat (or E.
coli CC03-9003), BL21(DE3)/pUCtk-pvmat (or E. coli CC03-9004), and
BL21(DE3)/pUCtk-ylmat (or E. coli CC03-9005), BL21(DE3)/pUCtk-cgmat (or
E. coli CC03-9006). Further, the transformants were deposited to the Korean
Culture Center of Microorganisms (KCCM) on July 15, 2016 under the Budapest
Treaty, and received the deposit numbers KCCM11863P, KCCM11864P,
KCCM11865P, KCCM11866P, KCCM11867P, and KCCM11868P, respectively,
according to the above-described order.
In order to examine the N-acetylmethionine producing capacity of the
selected transformed Escherichia coli, one colony was inoculated in 3 mL of an LB
liquid medium containing 25 mg/L of kanamycin and 0.2% (w/v) of glucose,
cultured at 37 C for 5 hours, and then further cultured for 3 hours with the addition
of methionine up to 2% (w/v), so as to obtain 1 µL of a culture solution. The
production of N-acetylmethionine was previously examined by thin layer
chromatography (TLC) analysis using 1 μL of the culture solution. Spots
presumed to be N-acetylmethionine were found in the entire culture solution, the
concentration of the spots increased in the order of BL21(DE3)/pUCtk-ppmat,
BL21(DE3)/pUCtk-entmat, BL21(DE3)/pUCtk-bsmat, BL21(DE3)/pUCtk-cgmat,
BL21(DE3)/pUCtk-pvmat, and BL21(DE3)/pUCtk-ylmat.
[Table 2]
Example 2-2: Confirmation of N-acetylmethionine production
capacity using novel acyltransferase
One colony of the transformed Escherichia coli prepared in Example 2-1
was inoculated in 3 mL of an LB liquid medium containing 25 mg/L of kanamycin
and 0.2% (w/v) of glucose and cultured at 37°C for 8 hours, and then inoculated in
50 mL of the same medium and cultured overnight, so as to obtain a culture
solution. The culture solution was centrifuged to obtain pellets, the pellets were
suspended in 5 mL of a 50 mM phosphate buffer (pH 7.0), and then cells were
disrupted using sonication to obtain cell debris. The cell debris was removed by
centrifugation at 14,000 rpm for 30 minutes to obtain a supernatant. Considering
that the size of the novel acyltransferase is about 19 kDa, the filtrate was passed
through an Amicon Ultra (Milipore, Ireland) 30 kDa cut-off membrane and then
through a 10 kDa cut-off membrane to obtain a concentrate remaining on the filter.
The concentrate filled a HiTrap Q FF column (GE, USA) filled with Q sepharose,
the novel acyltransferase was purely separated using NaCl concentration gradients
(80, 100, 150, 200, 300, 500 mM, in that order). The diluted enzyme was re-
concentrated through an Amicon Ultra 10 kDa cut-off membrane. The degree of
overexpression and purification of the novel acyltransferase was confirmed by
SDS-PAGE.
In order to analyze the activity of the purified novel acyltransferase, the
amount of the N-acetylmethionine produced after introducing an enzyme
concentrate into a pH 7.0 phosphate buffer containing 20 mM acetyl coenzyme A
and 20 mM methionine and performing a reaction at 37 C for 10 minutes was
measured using HPLC (Shimadzu, system controller CBM-20A and other
accessories). Further, the concentration of the purified novel acyltransferase was
measured by a Bradford assay, and then the produced N-acetylmethionine value
was divided by the enzyme concentration to compare the specific activity of the
enzyme (Table 3).
Among the purified novel acyltransferases, the Pseudomonas putida-
derived enzyme exhibits the highest activity of 3.8 U/mg, which is 5 times specific
activity (0.745 U/mg) of YncA disclosed in the document (US 8143031 B2, Table
3). In addition, the Bacillus subtilis-derived enzyme and the Enterobacter sp.
638-derived enzyme exhibit activities of 1.6 U/mg and 1.7 U/mg, respectively,
each of which is 2 or more times specific activity of YncA. Each of the
Pseudovibrio sp. FO-BEG1-derived, Yarrowia lipolytica-derived, and
Corynebacterium glutamicum-derived novel acyltransferases has low specific
activity of less than 1 U/mg, but the expression amount thereof on SDS-PAGE is
not so small. Therefore, the N-acetylmethionine producing capacity of the
transformant may be expected to be improved depending on the degree of
expression in the host (Table 3).
[Table 3]
Acyltransferase Specific activity (U/mg)
Pseudomonas putida-derived 3.8
Bacillus subtilis-derived 1.6
Enterobacter sp. 638-derived 1.7
Pseudovibrio sp. FO-BEG1-derived 0.4
Yarrowia lipolytica PO1f-derived 0.4
Corynebacterium glutamicum-derived 0.8
Example 3: N-Acetylmethionine conversion reaction using
Pseudomonas putida-derived novel acyltransferase
Example 3-1: N-Acetylmethionine conversion reaction using
Pseudomonas putida-derived purified novel acyltransferase
A methionine conversion reaction was performed using 1 mg of the
Pseudomonas putida-derived purified acyltransferase, which had the highest
activity in Example 2. 3 ml of a 50 mM phosphate buffer of pH 7.0 containing
mM methionine and 20 mM acetyl coenzyme A was used as a substrate solution.
When the reaction solution was analyzed by HPLC (SHIMADZU, SYSTEM
CONTROLLER CBM-20A and other accessories) after reaction for 3 hours under
conditions of 37 C and 150 rpm, the production of 3.1 g/L of N-acetylmethionine
was confirmed. This is a value obtained by converting methionine and acetyl
coenzyme A in the reaction solution by 75% or more.
Example 3-2: N-Acetylmethionine conversion reaction of cell provided
therein with Pseudomonas putida-derived acyltransferase depending on
increase of cell membrane permeability
One colony of the transformed Escherichia coli BL21(DE3)/pUCtk-ppmat
made by introducing the Pseudomonas putida-derived novel acyltransferase gene
prepared in Example 2 was inoculated in 3 ml of an LB liquid medium containing
25 mg/L of kanamycin and 1% (w/v) of glucose and cultured at 37°C for 8 hours to
obtain a culture solution, and then 50 µL of the culture solution was inoculated in
50 mL of an LB liquid medium containing 25 mg/L of kanamycin and 0.2% (w/v)
of glucose and cultured overnight. The culture solution was centrifuged to obtain
cell pellets, the cell pellets were frozen in a refrigerator at -20°C. The processes
of remelting the fully frozen cell pellets at room temperature and refreezing these
cell pellets were repeated three times to impart high permeability to the cell
membrane. The culture solution was resuspended to a total volume of 5 mL by
adding a 50 mM phosphate buffer (pH 7.0) to concentrate the culture solution.
1.8 mL of a 50 mM phosphate buffer (pH 7.0) containing 2% (w/v) methionine;
1.8 mL of a 50 mM phosphate buffer (pH 7.0) containing 2% (w/v) methionine and
mM acetyl coenzyme A; and 1.8 mL of a 50 mM phosphate buffer (pH 7.0)
containing 2% (w/v) methionine and 2% (w/v) glucose were respectively put into
mL test tubes, and were each mixed with the enzyme bacteria having improved
cell membrane permeability obtained through the above procedures by 200 µL to a
total volume of 2 mL, and were then reacted for 10 hours under conditions of 37°C
and 150 rpm. The purpose of adding glucose to the reaction solution is to
increase the production amount of acetyl coenzyme A, which may be deficient in
the reaction, and is not intended for the survival of Escherichia coli. The reaction
solution was analyzed by HPLC (SHIMADZU, SYSTEM CONTROLLER CBM-
20A and other accessories), and the results thereof are given in Table 4. As given
in Table 4, it was found that when the acetyl coenzyme A was added at the time of
fermentation, the molar conversion rate of the reaction solution was increased
compared to when the acetyl coenzyme A was not added. Further, since it was
found that the molar conversion rate of the reaction solution was increased even
when sucrose was added instead of the acetyl coenzyme A, it was estimated that
the addition of glucose makes a portion of the acetyl coenzyme A. As the result
of using strains each having a high-permeability cell membrane, N-
acetylmethionine was able to be produced at high concentration, and was also able
to be produced at high concentration even when only glucose was added to the
medium instead of the acetyl coenzyme A.
[Table 4]
Addition in reaction N-Acetylmethionine Molar conversion rate
solution concentration (g/L) (%)
Not added 13.1 51
Acetyl coenzyme A 20.0 78
Glucose 18.7 73
Example 4: Production of N-acetyl-L-methionine through
fermentation of transformant provided therein with novel acyltransferase
Example 4-1: Production of N-acetyl-L-methionine through
Escherichia coli provided therein with novel acyltransferase
One of the colonies of the six kinds of transformants prepared in Example
2 was inoculated in 3 mL of an LB liquid medium containing 25 mg/L of
kanamycin and 1% (w/v) of glucose and cultured at 37 C for 8 hours to obtain a
culture solution, and then the culture solution was inoculated in 50 mL of an LB
liquid medium containing 25 mg/L of kanamycin, 0.2% (w/v) of glucose, and
2% (w/v) of methionine and cultured overnight. In this case, as a control group, a
pUCtk empty vector was transformed into BL21 (DE3) and used. After the cells in
the culture solution were removed by centrifugation, the produced N-
acetylmethionine was analyzed using HPLC (SHIMADZU, SYSTEM
CONTROLLER CBM-20A and other accessories). In the case of
BL21(DE3)/pUCtk-ppmat, N-acetylmethionine was produced at the highest
concentration of 3.03 g/L. In the case of BL21(DE3)/pUCtk-entmat, N-
acetylmethionine was produced at the second highest concentration of 2.23 g/L.
Even in the case of the empty vector, a trace amount of N-acetylmethionine was
detected, which is presumed to be a role of the YncA enzyme possessed by
Escherichia coli (Table 5).
[Table 5]
Transformant Concentration of N-acetylmethionine in
culture solution (g/L)
BL21(DE3)/pUCtk < 0.1
BL21(DE3)/pUCtk-ppmat 3.03
BL21(DE3)/pUCtk-bsmat 1.60
BL21(DE3)/pUCtk-entmat 2.23
BL21(DE3)/pUCtk-pvmat 0.17
BL21(DE3)/pUCtk-ylmat 0.13
BL21(DE3)/pUCtk-cgmat 0.58
Example 4-2: Production of N-acetyl-L-methionine through
Corynebacterium provided therein with novel acyltransferase
Example 41: Preparation of acyltransferase overexpression vector
for introducing microorganism of genus Corynebacterium
In order to examine the effect of N-acetyl-L-methionine production of the
novel acyltransferases (SEQ ID NOS. 1, 2, 3, 4, 5, and 6) confirmed from Example
1 in microorganisms of genus Corynebacterium, vectors for overexpressing the
corresponding genes were prepared. A primer in which an EcoRV restriction
enzyme site is inserted at the 5′ end and a primer in which a PstI site is inserted at
the 3′ end were synthesized based on base sequences 7, 8, 9, 10, 11, and 12.
The gene based on base sequence 7 was polymerized through PCR using
the vector pUCtk-ppmat of Example 1 as a template and using primers 5 and 6.
The gene based on base sequence 8 was polymerized through PCR using the vector
pUCtk-bsmat of Example 1 as a template and using primers 7 and 8. The gene
based on base sequence 9 was polymerized through PCR using the vector pUCtk-
entmat of Example 1 as a template and using primers 9 and 10. The gene based
on base sequence 10 was polymerized through PCR using the vector pUCtk-pvmat
of Example 1 as a template and using primers 11 and 12. The gene based on base
sequence 11 was polymerized through PCR using the vector pUCtk-ylmat of
Example 1 as a template and using primers 13 and 14. The gene based on base
sequence 12 was polymerized through PCR using the vector pUCtk-cgmat of
Example 1 as a template and using primers 15 and 16.
As the promoter of the acyltransferase, a promoter cj7 (Korean
Unexamined Patent Application Publication No. 100107215) was used. In
order to obtain the DNA fragment of the cj7 promoter, a primer in which a KpnI
restriction enzyme is inserted at the 5′ end and a primer in which an EcoRV site is
inserted at the 3′ end were synthesized, and the cj7 promoter was amplified through
PCR using p117-cj1-gfp as a template (Korean Patent Application Publication
No. 100107215). In this case, PCR was performed by conducting
denaturation at 94 C for 5 minutes, repeating denaturation at 94 C for 30 seconds,
annealing at 56 C for 30 seconds and polymerization at 72 C for 1 minute 30 times,
and then conducting a polymerization reaction at 72 C for 7 minutes.
The six kinds of amplified acyltransferase polynucleotides were treated
with restriction enzyme PstI to obtain DNA fragments, and the cj7 promoter
polynucleotide was treated with KpnI and EcoRV to obtain a DNA fragment.
After six DNA fragments were obtained, they were linked to the Kpnl and Pstl sites
of the pECCG117 vector, which is a shuttle vector of Escherichia and
Corynebacterium, to be transformed into Escherichia coli DH5α, and were
smeared in an LB solid medium containing kanamycin (25 mg/L). The colonies
transformed with the vector into which the gene was inserted were selected by PCR,
and then plasmids were obtained using a generally known plasmid extraction
method. The obtained plasmids were named pECCG117-Pcj7-ppmat,
pECCG117-Pcj7-bsmat, pECCG117-Pcj7-entmat, pECCG117-Pcj7-pvmat,
pECCG117-Pcj7-ylmat, and pECCG117-Pcj7-cgmat.
Example 42: Preparation of strain for introducing novel
acyltransferase overexpression vector and confirmation of N-acetyl-L-
methionine production capacity
Each of the vectors pECCG117-Pcj7-ppmat, pECCG117-Pcj7-bsmat,
pECCG117-Pcj7-entmat, pECCG117-Pcj7-pvmat, pECCG117-Pcj7-ylmat, and
pECCG117-Pcj7-cgmat, prepared in Example 41, and vector pECCG117 of the
experimental control group was introduced into the Corynebacterium glutamicum
ATCC13032 using an electric pulse method, smeared in a composite plate medium
containing kanamycin (25 mg/L), and then cultured at 30 C for 24 hours to obtain
strains. The obtained strains were named 13032/pECCG117-Pcj7-ppmat,
13032/pECCG117-Pcj7-bsmat, 13032/pECCG117-Pcj7-entmat,
13032/pECCG117-Pcj7-pvmat, 13032/pECCG117-Pcj7-ylmat, 13032/pECCG117-
Pcj7-cgmat, and 13032/pECCG117. In order to confirm the N-acetylmethionine
production capacity of the transformant, the strains were inoculated in 14 mL of a
disposable culture tube including 3 mL of a composite liquid medium containing
kanamycin (25 mg/L), and shake-cultured for 24 hours under conditions of 30 C
and 200 rpm to obtain a seed culture solution. 1 mL of the seed culture solution
was inoculated in a 250 mL corner-baffle flask including 24 mL of a composite
liquid medium containing kanamycin (25 mg/L) and methionine (2% (20 g/L)), and
shake-cultured for 24 hours under conditions of 37 C and 200 rpm. After
completing the culture, the concentration of N-acetylmethionine was analyzed
using HPLC (SHIMADZU, SYSTEM CONTROLLER CBM-20A and other
accessories) (Table 6).
In the case of the transformant 13032/pECCG117 prepared as a control
group, 1.07 g/L of N-acetylmethionine was produced. This result is presumed to
be caused by the ability of the acyltransferase possessed by Corynebacterium
glutamicum, which is a parent strain. Further, it can be ascertained that a larger
amount of N-acetylmethionine is produced as compared with original ability as the
result of overexpressing the six kinds of novel acyltransferases.
<Composite plate medium>
g glucose, 50 g (NH ) SO , 10 g peptone, 5 g yeast extract, 1.5 g urea,
4 2 4
5 g KH PO , 10 g K HPO , 0.5 g MgSO 7H O, 100 µg biotin, 1000 µg thiamine
2 4 2 4 4 2
HCl, 2000 µg calcium pantothenate, 2000 µg nicotinamide, 20 g agar, and 25 mg
kanamycin (based on 1 L distilled water)
<Composite liquid medium>
g glucose, 10 g peptone, 5 g yeast extract, 1.5 g urea, 4 g KH PO , 8 g
K HPO , 0.5 g MgSO 7H O, 100 µg biotin, 1000 µg thiamine HCl, 2000 µg
2 4 4 2
calcium pantothenate, 2000 µg nicotinamide, and 25 mg kanamycin (based on 1 L
distilled water)
[Table 6]
Transformant Concentration of N-acetylmethionine in
culture solution (g/L)
13032/pECCG117 1.07
13032/pECCG117-Pcj7-ppmat 2.50
13032/pECCG117-Pcj7-bsmat 1.79
13032/pECCG117-Pcj7-entmat 2.11
13032/pECCG117-Pcj7-pvmat 1.23
13032/pECCG117-Pcj7-ylmat 1.31
13032/pECCG117-Pcj7-cgmat 2.58
Example 4-3: Production of N-acetyl-L-methionine through
Saccharomyces provided therein with novel acyltransferase
Example 41: Preparation of acyltransferase overexpression vector
for Saccharomyces
In order to examine the effect of N-acetyl-L-methionine production of the
novel acyltransferases (SEQ ID NOS. 1, 2, 3, 4, 5, and 6) confirmed from Example
1 in Saccharomyces, vectors for overexpressing the corresponding genes were
prepared. A primer in which a SpeI restriction enzyme site is inserted at the 5′
end and a primer in which a XhoI site is inserted at the 3′ end were synthesized
based on base sequences 7, 8, 9, 10, 11, and 12.
The gene based on base sequence 7 was polymerized through PCR using
the vector pUCtk-ppmat of Example 1 as a template and using primers 17 and 18.
The gene based on base sequence 8 was polymerized through PCR using the vector
pUCtk-bsmat of Example 1 as a template and using primers 19 and 20. The gene
based on base sequence 9 was polymerized through PCR using the vector pUCtk-
entmat of Example 1 as a template and using primers 21 and 22. The gene based
on base sequence 10 was polymerized through PCR using the vector pUCtk-pvmat
of Example 1 as a template and using primers 23 and 24. The gene based on base
sequence 11 was polymerized through PCR using the vector pUCtk-ylmat of
Example 1 as a template and using primers 25 and 26. The gene based on base
sequence 12 was polymerized through PCR using the vector pUCtk-cgmat of
Example 1 as a template and using primers 27 and 28. In this case, the PCR was
performed by conducting denaturation at 94 C for 5 minutes, repeating
denaturation at 94 C for 30 seconds, annealing at 56 C for 30 seconds and
polymerization at 72 C for 1 minute 30 times, and then conducting a
polymerization reaction at 72 C for 7 minutes.
The six kinds of amplified acyltransferase polynucleotides were treated
with restriction enzymes SpeI and XhoI to obtain DNA fragments. After six DNA
fragments were obtained, they are linked to the SpeI and XhoI sites of the
p414ADH vector, which is a shuttle vector of Escherichia and Saccharomyces, to
be transformed into Escherichia coli DH5α, and were smeared in an LB solid
medium containing ampicillin (100 mg/L). The colonies transformed with the
vector into which the gene was inserted were selected by PCR, and then plasmids
were obtained using a plasmid miniprep kit (Bioneer, Korea). The obtained
plasmids were named p414ADH-ppmat, p414ADH-bsmat, p414ADH-entmat,
p414ADH-pvmat, p414ADH-ylmat, and p414ADH-cgmat.
Example 42: Preparation of strain for introducing novel
acyltransferase overexpression vector and confirmation of N-acetyl-L-
methionine production capacity
Each of the vectors p414ADH-ppmat, p414ADH-bsmat, p414ADH-
entmat, p414ADH-pvmat, p414ADH-ylmat, and p414ADH-cgmat, prepared in
Example 41, and vector pECCG117 of the experimental control group was
introduced into Saccharomyces cerevisiae CEN.PK2-1D (Korean Patent
Registration No. 10-1577134), which is a typical wild yeast received from
EUROSCARF, using a yeast transformation method. The vectors were
introduced into the Saccharomyces cerevisiae CEN.PK2-1D, and then smeared in a
YPD plate medium (1% yeast extract, 2% bacto-peptone, 2% glucose), and
cultured at 30 C for 24 hours to obtain strains. The obtained strains were named
ScCEN/p414ADH-ppmat, ScCEN/p414ADH-bsmat, ScCEN/p414ADH-entmat,
ScCEN/p414ADH-pvmat, ScCEN/p414ADH-ylmat, ScCEN/p414ADH-cgmat, and
ScCEN/p414ADH. In order to confirm the N-acetylmethionine production
capacity of the transformant, the strains were inoculated in 14 mL of a disposable
culture tube including 3 mL of a YPD liquid medium containing ampicillin
(100 mg/L), and shake-cultured for 24 hours under conditions of 30 C and 200 rpm
to obtain a seed culture solution. 1 mL of the seed culture solution was inoculated
in a 250 mL corner-baffle flask including 24 mL of a YPD liquid medium
containing methionine (0.5% (5 g/L)), and shake-cultured for 24 hours under
conditions of 30C and 200 rpm. After completing the culturing, the
concentration of N-acetyl-L-methionine was analyzed using HPLC (SHIMADZU,
SYSTEM CONTROLLER CBM-20A and other accessories) (Table 7).
In the case of the transformant 13032/pECCG117 prepared as a control
group, 1.07 g/L of N-acetylmethionine was produced. This result is presumed to
be caused by the ability of the acyltransferase possessed by Corynebacterium
glutamicum, which is a parent strain. Further, it can be ascertained that a larger
amount of N-acetylmethionine is produced as compared with the original ability as
a result of overexpressing the six kinds of novel acyltransferases.
As can be seen from the transformant ScCEN / p414ADH, it is presumed
that Saccharomyces cerevisiae itself does not produce N-acetylmethionine, but it
was ascertained that the strains in which six kinds of novel acyltransferases are
overexpressed have N-acetylmethionine production capacity.
[Table 7]
Transformant Concentration of N-acetylmethionine in
culture solution (g/L)
ScCEN/p414ADH 0
ScCEN/p414ADH-ppmat 1.64
ScCEN/p414ADH-bsmat 1.44
ScCEN/p414ADH-entmat 1.65
ScCEN/p414ADH-pvmat 0.42
ScCEN/p414ADH-ylmat 1.40
ScCEN/p414ADH-cgmat 0.30
Example 4-4: Production of N-acetyl-L-methionine through Yarrowia
provided therein with novel acyltransferase
Example 41: Preparation of acyltransferase overexpression vector
for Yarrowia
In order to examine the effect of N-acetyl-L-methionine production of the
novel acyltransferases (SEQ ID NOS. 1, 2, 3, 4, 5, and 6) confirmed from Example
1 in Yarrowia, vectors for overexpressing the corresponding genes were prepared.
A primer in which a KpnI restriction enzyme site is inserted at the 5′ end and a
primer in which a KpnI restriction enzyme site is inserted at the 3′ end were
synthesized based on base sequences 7, 8, 9, 10, 11, and 12.
The gene based on base sequence 7 was polymerized through PCR using
the vector pUCtk-ppmat of Example 1 as a template and using primers 29 and 30.
The gene based on base sequence 8 was polymerized through PCR using the vector
pUCtk-bsmat of Example 1 as a template and using primers 31 and 32. The gene
based on base sequence 9 was polymerized through PCR using the vector pUCtk-
entmat of Example 1 as a template and using primers 33 and 34. The gene based
on base sequence 10 was polymerized through PCR using the vector pUCtk-pvmat
of Example 1 as a template and using primers 35 and 36. The gene based on base
sequence 11 was polymerized through PCR using the vector pUCtk-ylmat of
Example 1 as a template and using primers 37 and 38. The gene based on base
sequence 12 was polymerized through PCR using the vector pUCtk-cgmat of
Example 1 as a template and using primers 39 and 40. In this case, the PCR was
performed by conducting denaturation at 94 C for 5 minutes, repeating
denaturation at 94 C for 30 seconds, annealing at 56 C for 30 seconds and
polymerization at 72 C for 1 minute 30 times, and then conducting a
polymerization reaction at 72 C for 7 minutes.
The six kinds of amplified acyltransferase polynucleotides were treated
with restriction enzyme KpnI to obtain DNA fragments. After six DNA
fragments were obtained, they are linked to the KpnI site of a shuttle vector
pIMR53_AUX (FEMS Microbiology LettersVolume 199, Issue 1, pages 97-102,
May 2001) of Escherichia and Yarrowia, to be transformed into Escherichia coli
DH5α, and were smeared in an LB solid medium containing ampicillin (100 mg/L).
The colonies transformed with the vector into which the gene was inserted were
selected by PCR, and then plasmids were obtained using a plasmid miniprep kit
(Bioneer, Korea). The obtained plasmids were named pIMR53U-ppmat,
pIMR53U-bsmat, pIMR53U-entmat, pIMR53U-pvmat, pIMR53U-ylmat, and
pIMR53U-cgmat.
Example 42: Preparation of strain for introducing acyltransferase
overexpression vector and confirmation of N-acetyl-L-methionine production
capacity
Each of the vectors pIMR53U-ppmat, pIMR53U-bsmat, pIMR53U-entmat,
pIMR53U-pvmat, pIMR53U-ylmat, and pIMR53U-cgmat, and vector
pIMR53_AUX of the experimental control group was introduced into Yarrowia
lipolytica PO1f (ATCC MYA-2613 ) purchased from American type Culture
Collection using a yeast transformation method. The vectors were introduced into
the Yarrowia lipolytica PO1f, and then smeared in a YPD plate medium (1% yeast
extract, 2% bacto-peptone, 2% glucose), and cultured at 30C for 24 hours to
obtain strains. The obtained strains were named Yl/pIMR53U-ppmat,
Yl/pIMR53U-bsmat, Yl/pIMR53U-entmat, Yl/pIMR53U-pvmat, Yl/pIMR53U-
ylmat, Yl/pIMR53U-cgmat, and Yl/pIMR53U. In order to confirm the N-
acetylmethionine production capacity of the transformant, the strains were
inoculated in 14 mL of a disposable culture tube including 3 mL of a YPD liquid
medium, and shake-cultured for 24 hours under conditions of 30 C and 200 rpm to
obtain a seed culture solution. 1 mL of the seed culture solution was inoculated in
a 250 mL corner-baffle flask including 24 mL of a YPDm liquid medium (10 g
glucose, 3.28 g Na HPO , 3.22 g NaH PO , 2 g yeast extract, and 50 g/L Proteose-
2 4 2 4
peptone) containing methionine (0.5% (5 g/L)), and shake-cultured for 24 hours
under conditions of 30 C and 200 rpm. After completing the culturing, the
concentration of N-acetyl-L-methionine was analyzed using HPLC (SHIMADZU,
SYSTEM CONTROLLER CBM-20A and other accessories) (Table 8).
It is presumed that N-acetylmethionine is also produced in the
transformant Yl/pIMR53U due to the effect of the acyltransferase possessed by the
wild type of Yarrowia lipolytica, but it was ascertained that the strains in which six
kinds of novel acyltransferases are overexpressed have N-acetylmethionine
production capacity.
[Table 8]
Transformant Concentration of N-acetyl-L-methionine
in culture solution (g/L)
YI/pIMR53U 1.02
YI/pIMR53U-ppmat 1.92
YI/pIMR53U-bsmat 1.78
YI/pIMR53U-entmat 1.82
YI/pIMR53U-pvmat 1.26
YI/pIMR53U-ylmat 2.01
YI/pIMR53U-cgmat 1.38
From the above results, it is suggested that acyltransferases newly
developed in the present disclosure and microorganisms including the same
efficiently produce N-acetyl-L-methionine as compared with a known
acyltransferase YncA.
As described above, those skilled in the art will be able to understand that
the present disclosure can be easily executed in other detailed forms without
changing the technical spirit or an essential feature thereof. Therefore, it should
be appreciated that the aforementioned embodiments are illustrative in all aspects
and are not restricted. The scope of the present disclosure is represented by
claims to be described below rather than the detailed description, and it is to be
interpreted that the meaning and scope of the claims and all changes or modified
forms derived from the equivalents thereof come within the scope of the present
disclosure.
Claims (9)
1. Use of a microorganism for preparing N-acetyl-L-methionine, the microorganism comprising a polypeptide having an acetyltransferase activity in which the polypeptide is represented by an amino acid sequence of any one of SEQ ID NOS: 5 1 to 3 or an amino acid sequence having 90% or more sequence identity to the amino acid sequence, wherein the microorganism is selected from the group consisting of Escherichia sp., Corynebacterium sp., Saccharomyces sp., and Yarrowia sp.
2. A modified microorganism producing N-acetyl-L-methionine, wherein 10 activity of an acetyltransferase represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 3 or an amino acid sequence having 90% or more sequence identity to the amino acid sequence is introduced or enhanced compared with its endogenous activity. 15
3. The microorganism according to claim 2, wherein the microorganism is selected from the group consisting of Escherichia sp., Corynebacterium sp., Saccharomyces sp., and Yarrowia sp.
4. Use of a polypeptide having an acetyltransferase activity for preparing N- 20 acetyl-L-methionine, the polypeptide being represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 3 or an amino acid sequence having 90% or more sequence identity to the amino acid sequence.
5. Use of an isolated polynucleotide encoding the polypeptide of claim 4 for 25 preparing N-acetyl-L-methionine.
6. Use of an expression vector comprising the isolated polynucleotide of claim 5 for preparing N-acetyl-L-methionine. 30
7. Use of a composition for preparing N-acetyl-L-methionine from L- methionine, the composition comprising: (i) the microorganism according to any one of claims 1 to 3 or a culture thereof; and (ii) the polypeptide according to claim 4.
8. A method of preparing N-acetyl-L-methionine, comprising: acetylating L-methionine using: (i) a polypeptide having an acetyltransferase activity in which the polypeptide is 5 represented by an amino acid sequence of any one of SEQ ID NOS: 1 to 3 or an amino acid sequence having 90% or more sequence identity to the amino acid sequence; (ii) a microorganism comprising the polypeptide having an acetyltransferase activity of (i), in which the microorganism is selected from the group consisting of 10 Escherichia sp., Corynebacterium sp., Saccharomyces sp., and Yarrowia sp, the microorganism of claim 2 or 3, or a culture thereof; or (iii) a combination thereof.
9. The method according to claim 8, further comprising: 15 recovering N-acetyl-L-methionine, which is the acetylated L-methionine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0092228 | 2016-07-20 | ||
KR1020160092228A KR101941745B1 (en) | 2016-07-20 | 2016-07-20 | Microorganisms having an acyltransferase activity and the use thereof |
PCT/KR2017/007770 WO2018016873A1 (en) | 2016-07-20 | 2017-07-19 | Microorganism having activity of acyltransferase and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ750131A NZ750131A (en) | 2021-05-28 |
NZ750131B2 true NZ750131B2 (en) | 2021-08-31 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5473927B2 (en) | Acetone production by fermentation from renewable raw materials via a novel metabolic pathway | |
US8124388B2 (en) | Production of 3-hydroxypropionic acid using beta-alanine/pyruvate aminotransferase | |
CA3095659A1 (en) | Isopropylmalate synthase variant and a method of producing l-leucine using the same | |
EP3490969A1 (en) | N-acetyl homoserine | |
KR20220021436A (en) | Novel Lysine Decarboxylase with High Catalytic Efficiency in Alkaline Condition and Method for Producing Cadaverine Using the same | |
US20220042000A1 (en) | Methods for preparing n-acetyl-l-methionine | |
JP5707318B2 (en) | Method for producing L-lysine | |
US20140296571A1 (en) | Microorganisms And Methods For Producing Propionic Acid | |
WO2013052717A2 (en) | Microorganisms and methods for producing acrylate and other products from homoserine | |
RU2694041C1 (en) | Embodiment of o-acetyl-homoserine-sulfhydrylase and method of producing l-methionine using this embodiment | |
RU2706535C2 (en) | O-acetyl-homoserine-producing microorganism, and method of producing o-acetyl-homoserine using said microorganism | |
CN114058560B (en) | Process for the production of glycine | |
NZ750131B2 (en) | Microorganism having acyltransferase activity and uses thereof | |
KR20220152728A (en) | Microorganism having inhanced activity of 3-methyl-2-oxobutanoate hydroxymethyltransferase and uses thereof | |
WO2006003015A2 (en) | Improved enzymes | |
US7198932B1 (en) | Gdp-4-keto-6-deoxy-d-mannose-3,5-epimerase-4-reductase gene derived from arabidopsis thaliana | |
KR20220030866A (en) | Mutant of Corynebacterium glutamicum with enhanced L-lysine productivity and method for preparing L-lysine using the same | |
JP2021524262A (en) | Method for producing D-xylose dehydrogenase and D-xylonate derived from coryneform bacteria (Hersterung) | |
KR20210002260A (en) | A method of producing sulfur-containing amino acids and derivatives thereof | |
NO330796B1 (en) | Protein, polynucleotide, polynucleotide sequence, recombinant vector, non-human host, and methods for producing D-phenyl lactic acid hydrogenase, D-phenyl lactic acid and substance PF1022 or derivatives thereof |